Immunogenic Potential of Chitosan Nanoparticles Encapsulating Recombinant SlyB Antigen of Enterotoxigenic Escherichia coli (ETEC) in an Animal Model

Document Type : Original Articles

Authors

1 Department of Microbiology, Faculty of Basic Sciences, Shahrekord Branch, Islamic University, Shahrekord Branch, Iran.

2 Baqiyatallah University of Medical Sciences, Tehran, Iran

3 Department of Microbiology, Faculty of Basic Sciences, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran.

10.32592/ARI.2025.80.1.169

Abstract

Intestinal bacterial infections are a significant cause of mortality in developing countries, with Enterotoxigenic Escherichia coli (ETEC) being a leading cause of severe diarrheal diseases. These infections are characterized by the production of enterotoxins and colonization factors that disrupt the small intestine, leading to diarrhea. While antibiotic treatments face limitations, vaccination has emerged as a critical tool for prevention. This study evaluates the immunogenicity of chitosan nanoparticles (NPs) encapsulating the recombinant surface antigen SlyB of ETEC in an animal model.
The SlyB antigen was expressed in an expression vector, purified, and encapsulated into chitosan nanoparticles using the ionic gelation method. Rabbits were immunized using three administration methods: oral, oral-injection, and injection. Antibody levels in serum and feces were measured via ELISA, and the neutralization ability of immune sera was assessed using an ileal loop assay.
Results demonstrated significant titers of serum IgG and fecal IgA antibodies across all immunized groups, with the oral administration of chitosan nanoparticles eliciting the highest IgA responses in mucosal surfaces. Encapsulation of the recombinant SlyB protein in chitosan NPs enhanced antigen stability, promoted controlled release, and stimulated robust cellular and humoral immunity. The challenge test confirmed the efficacy of immune sera in neutralizing ETEC toxins, particularly in orally vaccinated groups.
This study highlights the potential of chitosan nanoparticles as an effective delivery platform for mucosal vaccines against ETEC. By encapsulating recombinant antigens, this method not only enhances immunogenicity but also offers a promising alternative to conventional vaccination strategies for diarrheal diseases. Further research is recommended to explore scalability and efficacy in broader populations.

Keywords

Main Subjects

References

  1. Concha C, Cañas R, Macuer J, Torres MJ, Herrada AA, Jamett F, et al. Disease Prevention: An Opportunity to Expand Edible Plant-Based Vaccines? Vaccines. 2017;5(2):14.
  2. Pokharel P, Dhakal S, Dozois CM. The Diversity of Escherichia coli Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen. Microorganisms. 2023;11(2):344.
  3. Leitner DR, Lichtenegger S, Temel P, Zingl FG, Ratzberger D, Roier S, et al. A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles. Front Microbiol. 2015;6:823.
  4. Eguchi Y, Itou J, Yamane M, Demizu R, Yamato F, Okada A, et al. B1500, a small membrane protein, connects the two-component systems EvgS/EvgA and PhoQ/PhoP in Escherichia coli. Proc Natl Acad Sci U S A. 2007;104(47):18712–7.
  5. Gruenheid S, Le Moual H. Resistance to antimicrobial peptides in Gram-negative bacteria. FEMS Microbiol Lett. 2012 May;330(2):81–9.
  6. Perez JC, Shin D, Zwir I, Latifi T, Hadley TJ, Groisman EA. Evolution of a bacterial regulon controlling virulence and Mg (2+) homeostasis. PLoS Genet. 2009;5(3):e1000428.
  7. Kravchenko U, Gogoleva N, Kalubaka N, Kruk A, Diubo Y, Gogolev Y, et al. The PhoPQ Two-Component System Is the Major Regulator of Cell Surface Properties, Stress Responses and Plant-Derived Substrate Utilisation During Development of Pectobacterium versatile-Host Plant Pathosystems. Front Microbiol.
  8. Concha C, Cañas R, Macuer J, Torres MJ, Herrada AA, Jamett F, et al. Disease Prevention: An Opportunity to Expand Edible Plant-Based Vaccines? Vaccines. 2017;5(2):14.
  9. The Diversity of Escherichia coli Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen. Microorganisms. 2023;11(2):344.
  10. Leitner DR, Lichtenegger S, Temel P, Zingl FG, Ratzberger D, Roier S, et al. A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles. Front Microbial. 2015; 6:823.

11.Perez JC, Shin D, Zwir I, Latifi T, Hadley TJ, Groisman EA. Evolution of a bacterial regulon controlling virulence and Mg (2+) homeostasis. PLoS Genet. 2009;5(3): e1000428.

  1. Alo K, Nikbakhat G., Lotfollahzadeh S, Moosakhani F, Gharabaghi A. Passive protective effect of anti-K99 antibodies against enterotoxigenic E. coli infection in neonatal calves. Iranian Journal of Veterinary Medicine, 2018; 12(2): 97-107. 
  2. Kurup VM, Thomas J. Edible Vaccines: Promises and Challenges. Mol Biotechnol. 2020;62(2):79–90.
  3. Shi N, Li N, Duan X, Niu H. Interaction between the gut microbiome and mucosal immune system. Mil Med Res. 2017; 4:14.
  4. Mirhoseini A, Amani J, Nazarian S. Review on pathogenicity mechanism of enterotoxigenic Escherichia coli and vaccines against it. Microbial pathogenesis. 2018;117:162-9.
  5. Anvar, S. A. A., Nowruzi, B., Afshari, G. A Review of the Application of Nanoparticles Biosynthesized by Microalgae and Cyanobacteria in Medical and Veterinary Sciences. Iranian Journal of Veterinary Medicine, 2023; 17(1): 1-18.
  6. Ou B, Yang Y, Lv H, Lin X, Zhang M. Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines. BioDrugs Clin Immunother Biopharm Gene Ther. 2023;37(2):143–80.
  7. Dilnawaz F, Acharya S, Kanungo A. A clinical perspective of chitosan nanoparticles for infectious disease management. Polym Bull Berl Ger. 2023;1–25.
  8. Molecular Cloning: A Laboratory Manual (Fourth Edition), Volume 1, 2 & 3: Medicine & Health Science Books @ Amazon.com [Internet]. [cited 2023 Aug 11].
  9. Ghaffari Marandi BH, Zolfaghari MR, Kazemi R, Motamedi MJ, Amani J. Immunization against Vibrio cholerae, ETEC, and EHEC with chitosan nanoparticle containing LSC chimeric protein. Microb Pathog. 2019;134:103600.
  10. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.
  11. Gilavand F, Marzban A, Ebrahimipour G, Soleimani N, Goudarzi M. Designation of chitosan nano-vaccine based on MxiH antigen of Shigella flexneri with increased immunization capacity. Carbohydr Polym. 2020;232:115813.
  12. Fasihi-Ramandi M, Ghobadi-Ghadikolaee H, Ahmadi-Renani S, Taheri RA, Ahmadi K. Vibrio cholerae lipopolysaccharide loaded chitosan nanoparticle could save life by induction of specific immunoglobulin isotype. Artif Cells Nanomedicine Biotechnol. 2018;46(1):56–61.
  13. Najminejad H, Kalantar SM, Mokarram AR, Dabaghian M, Abdollahpour-Alitappeh M, Ebrahimi SM, et al. Bordetella pertussis antigens encapsulated into N-trimethyl chitosan nanoparticulate systems as a novel intranasal pertussis vaccine. Artif Cells Nanomedicine Biotechnol. 2019;47(1):2605–11.
  14. Zegeye ED, Diaz Y, Puntervoll P. Vaccine Candidate Double Mutant Variants of Enterotoxigenic Escherichia coli Heat-Stable Toxin. Vaccines. 2022;10(2):241.
  15. Stevens MP, van Diemen PM, Dziva F, Jones PW, Wallis TS. Options for the control of enterohaemorrhagic Escherichia coli in ruminants. Microbiol Read Engl. 2002;148(12):3767–78.
  16. Kwong KWY, Xin Y, Lai NCY, Sung JCC, Wu KC, Hamied YK, et al. Oral Vaccines: A Better Future of Immunization. Vaccines. 2023;11(7):1232.
  17. McGhee JR, Fujihashi K. Inside the Mucosal Immune System. PLoS Biol. 2012;10(9):e1001397.
  18. Mirtajaddini SA, Fathi Najafi M, Vaziri Yazdi SA, Kazemi Oskuee R. Preparation of Chitosan Nanoparticles as a Capable Carrier for Antigen Delivery and Antibody Production. Iran J Biotechnol. 2021;19(4):e2871.
  19. Almasian P, Amani J, Arani FB, Nazarian S, Kazemi R, Tabrizi NM. Preparation of chitosan nanoparticle containing recombinant StxB antigen of EHEC and evaluation its immunogenicity in BALB/c mice. Iran J Microbiol. 2018;10(6):361–70.
  20. Lee WJ, Cha S, Shin M, Jung M, Islam MA, Cho C su, et al. Efficacy of thiolated eudragit microspheres as an oral vaccine delivery system to induce mucosal immunity against enterotoxigenic Escherichia coli in mice. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV. 2012;81(1):43–8. 10
  21. Nazarian S, Gargari SLM, Rasooli I, Hasannia S, Pirooznia N. A PLGA-encapsulated chimeric protein protects against adherence and toxicity of enterotoxigenic Escherichia coli. Microbiol Res. 2014;169(2–3):205–12.
  22. Noroozi N, Gargari SLM, Nazarian S, Sarvary S, Adriani RR. Immunogenicity of enterotoxigenic Escherichia coli outer membrane vesicles encapsulated in chitosan nanoparticles. Iran J Basic Med Sci. 2018;21(3):284–91.
  23. Kordbacheh E, Nazarian S, Sadeghi D, Hajizadeh A. An LTB-entrapped protein in PLGA nanoparticles preserves against enterotoxin of enterotoxigenic Escherichia coli. Iranian Journal of Basic Medical Sciences. 2018;21(5):517.
  24. Khanifar J, Salmanian AH, Haji Hosseini R, Amani J, Kazemi R. Chitosan nano-structure loaded with recombinant E. coli O157: H7 antigens as a vaccine candidate can effectively increase immunization capacity. Artificial Cells, Nanomedicine, and Biotechnology. 2019;47(1):2593-604.
  25. Zhang C, Chen F, Liu X, Han X, Hu Y, Su X, Chen Y, Sun Y, Han L. Gliotoxin induces cofilin phosphorylation to promote actin cytoskeleton dynamics and internalization of Aspergillus fumigatus into type II human pneumocyte cells. Frontiers in Microbiology. 2019;10:1345.
  26. Williams AJ, Warfel KF, Desai P, Li J, Lee JJ, Wong DA, Nguyen PM, Qin Y, Sobol SE, Jewett MC, Chang YF. A low-cost recombinant glycoconjugate vaccine confers immunogenicity and protection against enterotoxigenic Escherichia coli infections in mice. Frontiers in Molecular Biosciences. 2023; 2(10):1085887.
  27. Lee WI, Huang JL, Lin SJ, Yeh KW, Chen LC, Ou LS, Yao TC, Jaing TH, Shih YF, Wu CY. Lower T regulatory and Th17 cell populations predicted by RT-PCR-amplified FOXP3 and ROR γ t genes are not rare in patients with primary immunodeficiency diseases. Frontiers in Immunology. 2020;25(11):1111.
  28. Brumfield K, Seo H, Idegwu N, Artman C, Gonyar L, Nataro J, Zhang W, Sack D, Geyer J, Goepp J. Feasibility of avian antibodies as prophylaxis against enterotoxigenic escherichia coli colonization. Frontiers in immunology. 2022;19(13):1011200.
Archives of Razi Institute
Volume 80, Issue 1
January and February 2025
Pages 169-178

Files

Share

How to cite

Statistics